BTAIQ BioXcel Therapeutics, Inc.
Debt Financing ·
The Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date.
The company said the FDA accepted its IGALMI at-home sNDA with a November 14, 2026 PDUFA date, and that it is reviewing strategic options. First quarter net loss was $12.7 million.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $642,000 | $2.3 million |
| Research and development | $30.3 million | $30.4 million |
| Net income (loss) | -$69.9 million | -$59.6 million |
| Cash from operations | -$57.6 million | -$72.0 million |
| Cash and equivalents | $28.4 million | $29.9 million |
BioXcel Therapeutics, Inc. trades under the ticker BTAIQ on OTC.
BioXcel Therapeutics, Inc. is listed on OTC.
Our directory records BioXcel Therapeutics, Inc. under United States.
aibio.space lists BioXcel Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$642,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
BioXcel Therapeutics, Inc. reported a net loss of $69.9 million for the fiscal year ended Dec 31, 2025, and used $57.6 million of cash in operations, per its annual report to the SEC.
$30.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
$12.8 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on BioXcel Therapeutics, dated Jul 6, 2026: "BioXcel amends its credit agreement and forms a strategic process committee". The Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date. Source.
Our latest debt story, dated Jul 6, 2026: "BioXcel amends its credit agreement and forms a strategic process committee". The Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date. Source.
From our story of May 15, 2026: The release gives no cash runway estimate, and approval of the at-home label is not assured. Source.
Press Follow on this page to add BioXcel Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming BioXcel Therapeutics so far, in Company Updates, Debt Financing.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,5.02,5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.03,3.01). Source
Reported a bankruptcy filing. SEC Form 8-K (Items 1.01,1.03). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio